"The pharmaceutical industry is at a crossroads where technological innovation is moving at one speed, and regulation at a very different one . To analyze this landscape, representatives from Veeva Systems—Anthony Corso, Vice President of Public Policy; Crystal Allard, Regulatory Strategist and former FDA official; and Werner Engelbrecht, Director of Clinical Strategy—met in a roundtable discussion at the Veeva Summit 2026 , which explored the challenges of a world seeking to eliminate paper in clinical development management but fearing artificial intelligence (AI)."
Read the full interview published by Cristian Galletos in Graceta de Salud
A version of this story was also written for MioPharma Blog, by Dino Biselli.